Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1070 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2025-04-26 (nature.com)
Nitro-oleic acid enhances mitochondrial metabolism and ameliorates heart failure with preserved ejection fraction in mice | Communications
The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing, while treatment options are inadequate. Hypertension and obesity-related metabolic dysfunction contribute to HFpEF. Nitro-oleic acid (NO2-OA) impacts metabolic syndromes by improving glucose tolerance and adipocyte function. Here we show that treatment with NO2-OA ameliorates diastolic dysfunction and heart failure symptoms in a HFpEF mouse model induced by high-fat diet and inhibition of the endothelial nitric oxide synthase. Proteomic analysis of left ventricular tissue reveals that one-third of identified proteins, predominantly mitochondrial, are upregulated in hearts of NO2-OA-treated HFpEF mice compared to naïve and vehicle-treated HFpEF mice. Increased mitochondrial mass and numbers, and enhanced mitochondrial respiration are linked with this response, as assessed by transmission electron microscopy and high-resolution respirometry.
Read more
2025-04-22 (biospace.com)
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development -
Utilizing a fully human platform, the company expands in vitro assays to develop a more translational offering
Read more
2025-04-14 (stockstotrade.com)
Pharma Boom: Charles River Drives Innovation -
Charles River Laboratories International Inc.'s stock has been trading up by 6.21 percent, driven by strong market optimism. Pioneering Drug Discovery: Advancing Lupus Treatment A significant breakthrough for lupus treatment is on the horizon, as Charles River teams up with Valo Health. Utilizing the AI platform, Logica, they have identified a promising product candidate. This…
Read more
2025-03-26 (nature.com)
Proteostasis and lysosomal repair deficits in transdifferentiated neurons of Alzheimer's disease | Cell Biology
Ageing is the most prominent risk factor for Alzheimer's disease (AD). However, the cellular mechanisms linking neuronal proteostasis decline to the characteristic aberrant protein deposits in the brains of patients with AD remain elusive. Here we develop transdifferentiated neurons (tNeurons) from human dermal fibroblasts as a neuronal model that retains ageing hallmarks and exhibits AD-linked vulnerabilities. Remarkably, AD tNeurons accumulate proteotoxic deposits, including phospho-tau and amyloid β, resembling those in APP mouse brains and the brains of patients with AD. Quantitative tNeuron proteomics identify ageing- and AD-linked deficits in proteostasis and organelle homeostasis, most notably in endosome–lysosomal components. Lysosomal deficits in aged tNeurons, including constitutive lysosomal damage and ESCRT-mediated lysosomal repair defects, are exacerbated in AD tNeurons and linked to inflammatory cytokine secretion and cell death.
Read more
2024-10-02 (businesswire.com)
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica ® to Advance the Discovery of Novel Drugs for Neurological Disease
Charles River and Lundbeck enter agreement to utilize AI-powered Logica to advance the discovery of novel drugs for neurological disease.
Read more
2024-05-27 (nature.com)
Noninvasive imaging-guided ultrasonic neurostimulation with arbitrary 2D patterns and its application for high-quality vision restoration
Retinal degeneration, a leading cause of irreversible low vision and blindness globally, can be partially addressed by retina prostheses which stimulate remaining neurons in the retina. However, existing electrode-based treatments are invasive, posing substantial risks to patients and healthcare
Read more